Target family: LIMK subfamily (type: enzyme)
Target: LIM domain kinase 2

Ligand: compound 14 [PMID: 19831390] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.050000190734863 pIC50
Reference (Journal): Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma.
Published in: J Med Chem

Ligand: compound 22m [PMID: 19831390] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.100000381469727 pIC50
Reference (Journal): Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma.
Published in: J Med Chem

Ligand: compound 30 [PMID: 22902653] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.800000190734863 pIC50
Reference (Journal): Modulation of cofilin phosphorylation by inhibition of the Lim family kinases.
Published in: Bioorg Med Chem Lett

Ligand: compound 31 [PMID: 22902653] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.420000076293945 pIC50
Reference (Journal): Modulation of cofilin phosphorylation by inhibition of the Lim family kinases.
Published in: Bioorg Med Chem Lett

Ligand: compound 35 [PMID: 22902653] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.100000381469727 pIC50
Reference (Journal): Modulation of cofilin phosphorylation by inhibition of the Lim family kinases.
Published in: Bioorg Med Chem Lett

Ligand: LIMKi3 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pIC50
Reference (Journal): Inhibition of human prostate smooth muscle contraction by the LIM kinase inhibitors, SR7826 and LIMKi3.
Published in: Br J Pharmacol

Ligand: LIMKi3 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pIC50
Reference (Journal): LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells.
Published in: J Cell Biol

Ligand: LIMKi3 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pIC50
Reference (Journal): Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors.
Published in: Mol Cancer Ther

Ligand: LIMKi3 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pIC50
Reference (Journal): The actin-severing protein cofilin is downstream of neuregulin signaling and is essential for Schwann cell myelination.
Published in: J Neurosci

Ligand: ZAK inhibitor 6p (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.199999809265137 pKd
Reference (Journal): Design, Synthesis, and Structure-Activity Relationships of 1,2,3-Triazole Benzenesulfonamides as New Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) Inhibitors.
Published in: J Med Chem